Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumors

10 Sept 2022

Abstract excerpt

Abnormal CDK4/6-Rb-E2F signal transduction is a common finding in tumors and is a driving factor for the excessive proliferation of various tumor cells. PD-0332991, a highly specific, small molecule inhibitor for CDK4 and 6, has been shown to inhibit tumor growth by abrogating the phosphorylating capacity of CDK4/6 and suppressing Rb phosphorylation. It has been promoted for the treatment of breast cancer and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36087253
DOI: 10.1007/s13402-022-00714-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumorsPMID 36087253Read ↗

Cell cycle checkpoint revolution: targeted therapies in the fight against malignant tumorsSemantic proximity Read ↗

Role of senescence induction in cancer treatmentSemantic proximity Read ↗

Dual cyclin‐dependent kinase 4/6 inhibition by PD‐0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cellsSemantic proximity Read ↗

Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNASemantic proximity Read ↗

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesotheliomaSemantic proximity Read ↗

Cell cycle regulation and anticancer drug discoverySemantic proximity Read ↗

The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexesSemantic proximity Read ↗

Reviewing cancer’s biology: an eclectic approachSemantic proximity Read ↗

CDK4/6 inhibitor: from quiescence to senescenceSemantic proximity Read ↗

Fighting Carcinogenesis with Plant Metabolites by Weakening Proliferative Signaling and Disabling Replicative Immortality Networks of Rapidly Dividing and Invading Cancerous CellsSemantic proximity Read ↗

Oncogenic signals prime cancer cells for toxic cell growth during a G1 cell cycle arrestSemantic proximity Read ↗

Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.